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Antagonism between RSF1 and SR
proteins for both splice-site recognition
in vitro and Drosophila development
Emmanuel Labourier,1,5 Henri-Marc Bourbon,2,5 Imed-eddine Gallouzi,1,3 Maggy Fostier,2,4
Eric Allemand,1 and Jamal Tazi1,6
1Institut de Ge´ne´tique Mole´culaire, Centre National de la Recherche Scientifique (CNRS), F34293 Montpellier Cedex 5,
France; 2Centre de Biologie du De´veloppement, CNRS, Universite´ Paul Sabatier, F31062 Toulouse, France
Specific recognition of splice sites within metazoan mRNA precursors (pre-mRNAs) is a potential stage for
gene regulation by alternative splicing. Splicing factors of the SR protein family play a major role in this
regulation, as they are required for early recognition of splice sites during spliceosome assembly. Here, we
describe the characterization of RSF1, a splicing repressor isolated from Drosophila, that functionally
antagonizes SR proteins. Like the latter, RSF1 comprises an amino-terminal RRM-type RNA-binding domain,
whereas its carboxy-terminal part is enriched in glycine (G), arginine (R), and serine (S) residues (GRS domain).
RSF1 induces a dose-sensitive inhibition of splicing for several reporter pre-mRNAs, an inhibition that occurs
at the level of early splicing complexes formation. RSF1 interacts, through its GRS domain, with the RS
domain of the SR protein SF2/ASF and prevents the latter from cooperating with the U1 small nuclear
ribonucleoprotein particle (U1 snRNP) in binding pre-mRNA. Furthermore, overproduction of RSF 1 in the fly
rescues several developmental defects caused by overexpression of the splicing activator SR protein B52/
SRp55. Therefore, RSF1 may correspond to the prototypical member of a novel family of general splicing
repressors that selectively antagonize the effect of SR proteins on 5* splice-site recognition.
[Key Words: pre-mRNA splicing; RNA-binding proteins; SF2/ASF; U1 snRNP; RSF1; B52/SRp55]
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Pre-mRNA splicing is an essential step in the expression
of most metazoan protein-coding genes, often regulated
in a cell-type specific or developmental manner. The pre-
cision and efficiency of the splicing reaction result from
a dynamic series of interactions among the U1, U2, U4/
U6, and U5 small nuclear ribonucleoprotein (snRNP)
particles, non-snRNPs, and the pre-mRNA that lead to
the formation of the spliceosome, the ribonucleoprotein
structure in which the accurate excision of intervening
sequences (introns) takes place (Sharp 1994; Kra¨mer
1996; Staley and Guthrie 1998). Although most of the
biochemical events involved in constitutive pre-mRNA
splicing are being elucidated, the complex regulation un-
derlying the selection of alternative exons is less well
understood (Adams et al. 1996; Wang and Manley 1997).
Both structural features and sequence content of pre-
mRNAs appear to be involved (Green 1991). In the past
few years, a class of purine-rich exonic elements known
as exonic splicing enhancers (ESEs) has been identified in
a number of pre-mRNAs (Katz and Skalka 1990; Lav-
igueur et al. 1993; Sun et al. 1993a,b; Watakabe et al.
1993; Xu et al. 1993; Caputi et al. 1994; Dirksen et al.
1994, 1995; Tanaka et al. 1994; Ramchatesingh et al.
1995; Staffa and Cochrane 1995; Staffa et al. 1997). These
sequences are likely to play a critical role in the initial
recognition and pairing of the 58 and 38 splice sites (Tian
and Maniatis 1993; Staknis and Reed 1994; Berget 1995).
They are expected to bind a set of RNA-binding proteins
among which several members of the SR protein family
are known to influence the splice site choice (Lavigueur
et al. 1993; Sun et al. 1993b; Staknis and Reed 1994; Fu
1995; Manley and Tacke 1996; Liu et al. 1998).
Members of the highly conserved SR protein family of
splicing regulators (Zahler et al. 1992; Fu 1995; Manley
and Tacke 1996), including SRp20/X16/RBP1, SF2/ASF
(SRp30a), SC35 (SRp30b), and B52/SRp55 have modular
structures that consist of one or two RNA-recognition
motifs (RRMs) and a carboxy-terminal arginine (R)/ser-
ine (S)-rich domain (the so-called RS domain). They are
thought to be essential splicing factors, as SR proteins
individually can complement splicing-deficient cyto-
plasmic S100 extracts, which lack SR proteins but con-
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tain all other factors necessary for splicing (Ge et al.
1991; Krainer et al. 1991; Mayeda et al. 1992; Zahler et
al. 1992; Cavaloc et al. 1994). Both the RRM and the RS
domains are essential for the function of SR proteins as
splicing factors (Zamore et al. 1992; Ca`ceres and Krainer
1993; Zuo and Manley 1993; Wang et al. 1998). The RS
domain is responsible for specific protein–protein inter-
actions among RS domain-containing proteins (Wu and
Maniatis 1993; Amrein et al. 1994; Kohtz et al. 1994;
Zuo and Maniatis 1996), interactions thought to consti-
tute a bridge between 58 and 38 splice sites during splice-
site selection. Such protein contacts promote the bind-
ing of U1 snRNP to the 58 splice site and U2 snRNP
auxiliary factor 65-kD subunit (U2AF65) to the 38 splice
site at earliest stages of spliceosome assembly (Staknis
and Reed 1994; Reed 1996). At least where introns with
weak 38 splice sites are involved, binding of SR proteins
to an ESE may facilitate 38 splice-site complex formation
through interaction with U2AF (Zuo and Maniatis 1996).
Many of the SR proteins described previously can af-
fect usage of alternative 58 or 38 splice sites in a concen-
tration-dependent manner (Ge and Manley 1990; Krainer
et al. 1990; Tian and Maniatis 1993; Zahler et al. 1993;
Ca`ceres et al. 1994; Reed 1996). Both in vitro and in vivo,
a small increase in the concentration of SF2/ASF pre-
vents the inappropriate exon-skipping of certain pre-
mRNAs (Mayeda and Krainer 1992; Mayeda et al. 1993).
It has been shown also that high levels of SF2/ASF regu-
late alternative splicing by promoting the use of proxi-
mal versus distal 58 splice sites (Ge and Manley 1990;
Krainer et al. 1990). Additionally, targeted disruption of
SF2/ASF in chicken cells demonstrated that SF2/ASF is
required for viability, and this depletion of SF2/ASF af-
fects splicing of specific transcripts in vivo (Wang et al.
1996; Wang and Manley 1997). Similarly, mutants of the
B52 gene are homozygous lethal in Drosophila (Ring and
Lis 1994) and overexpression of the B52/SRp55 protein
causes severe phenotypes (Kraus and Lis 1994). There-
fore, the relative abundance of each SR protein and/or
the molar ratio of each SR protein to selective antago-
nists may determine the patterns of alternative splicing
of many genes expressed in a particular cell type. In
agreement with this, it has been observed that the rela-
tive amount of individual SR proteins varies in different
tissues (Zahler et al. 1993). As an example, the expres-
sion of mouse X16 mRNA is high in thymus, spleen, and
testes but is low or undetectable in liver, kidney, brain,
and heart (Zahler et al. 1993). Similarly, variable levels of
X16 and SC35 mRNAs are expressed in different cell
lines and stages of development (Ayane et al. 1991; Vel-
lard et al. 1992). The finding that competing levels of the
heterogeneous nuclear ribonucleoprotein (hnRNP) par-
ticle protein A1 could have opposing effects on SF2/ASF
(Mayeda and Krainer 1992; Mayeda et al. 1993; Ca`ceres
et al. 1994) led to the suggestion that the regulation of
the expression of a wide variety of genes by alternative
splicing may be accomplished at least in part by varia-
tion in the nuclear concentration of antagonistic splicing
factors. Identification and characterization of splicing
factors that counteract SR proteins may therefore be an
important step in understanding the mechanism for
regulation of gene expression by alternative splicing.
By adopting an oligonucleotide-directed molecular ap-
proach to seek for RNA-binding proteins possibly in-
volved in important developmental decisions, we have
identified three novel D. melanogaster RRM superfam-
ily proteins previously [referred to as Rox proteins (Brand
et al. 1995)], among which Rox21, renamed here RSF1
(for repressor splicing factor 1), exhibits extensive se-
quence identity (54%–58%) in its single amino-terminal
RRM with members of the SR protein family. RSF1 also
possesses a carboxy-terminal domain enriched in glycine
(G), arginine, and serine residues (GRS domain). Here we
show that the latter domain mediates specific interac-
tions with itself and with members of the SR protein
family. However, in vitro complementation assays show
that RSF1 inhibits splicing of several reporter pre-
mRNAs, an inhibition that can be selectively counter-
acted by purified SR proteins. These studies, together
with the finding that RSF1 acts as an SR protein antago-
nist in vivo, represent the first identification of a general
splicing repressor.
Results
RSF1 inhibits splicing by competing
with the SR proteins
The structural features of RSF1, its nuclear localization,
and association with a subset of actively transcribed re-
gions of giant polytene chromosomes (data not shown)
prompted us to seek a role of this protein in pre-mRNA
splicing. Our initial attempts to do this were based on
complementation experiments using a HeLa nuclear ex-
tract containing a low level of SR proteins, knowing that
RSF1 fails to have the ability of SR protein to restore the
splicing activity of the S100 extract (data not shown). To
assess the effect of RSF1 on pre-mRNA splicing, we first
used a model b-globin pre-mRNA substrate (b-3A1) that
has three copies of a high-affinity binding site for RSF1
established by SELEX analysis (E. Labourier, E. Alle-
mand, S. Brand, M. Fostier, J. Tazi, and H.-M. Bourbon,
unpubl.), inserted 20 bases downstream of the first in-
tron of b-globin. This reporter pre-mRNA substrate was
spliced efficiently in a HeLa nuclear extract (Fig. 2A,
lanes 2,14, below). However, when this preparation of
HeLa nuclear extract was supplemented with an excess
of purified recombinant glutathione S-transferase (GST)–
RSF1 fusion protein produced in Escherichia coli (Fig. 1,
lane 3), splicing was readily inhibited in a dose-depen-
dent manner (Fig. 2A, lanes 3,4). One trivial explanation,
that the recombinant protein preparation contained a
component that inhibited splicing, could be eliminated,
because GST alone (Fig. 1, lane 1) prepared under the
same conditions had no effect on splicing (Fig. 2A, lanes
11,12). No inhibition was observed either with heat-de-
natured GST–RSF1 (data not shown) or two truncated
versions of the protein in which the GRS or the RRM
domain was selectively removed (Figs. 1, lanes 4,5, and
2A, lanes 5–8). This result demonstrates a requirement
RSF1, a Drosophila antagonist of SR proteins
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for native protein conformation, as well as for the joint
presence of the RRM and the GRS domain, for the inhi-
bition of splicing. Furthermore, as the GRS-truncated
version (GST–RSF1DC) binds RNA in vitro (E. Labourier,
E. Allemand, S. Brand, M. Fostier, J. Tazi, and H.-M.
Bourbon, unpubl.), this joint requirement indicates that
splicing inhibition is not caused by mere nonspecific
binding to pre-mRNA. Additionally, because RSF1 and
Drosophila SR protein RBP1 (Kim et al. 1992) have ho-
mologous RRMs and similar size, we tested the effect of
complementing HeLa nuclear extract with purified
GST–RBP1 (Fig. 1, lane 2). This protein had no detectable
effect (Fig. 2A, lanes 9,10), even though it binds RNA in
vitro (data not shown). Furthermore, GST–RSF1 inhibits
splicing of b-globin pre-mRNA, which does not contain
high-affinity RSF1 binding sites (Fig. 2B, lanes 3,4), im-
plying that its splicing inhibition activity in vitro is not
likely to be restricted to reporter pre-mRNAs containing
RSF1-selected sequences. Using native gel electrophore-
sis to isolate splicing complexes, we were able to show
that the inhibition was at the level of spliceosome as-
sembly (data not shown). Taken together, our results
support the idea that the inhibition of splicing by GST–
RSF1 is related directly to its function as a general splic-
ing repressor that acts at an early stage of spliceosome
assembly.
Interestingly, a mixture of purified SR proteins (data
not shown) or purified SRp30 (Fig. 1, lane 6; note that
SRp30 contains both SF2/ASF and SC35 proteins) re-
stored full splicing activity of the RSF1-inhibited HeLa
nuclear extract in a concentration-dependent manner
(Fig. 2, A, lanes 16 and 17, and B, lanes 10 and 11). Com-
parison with known amounts of purified SRp30 indi-
cated that our preparation of HeLa nuclear extract con-
tained ~ 5 pmoles (110 ng) of SRp30 per microliter of ex-
tract. The concentration of GST–RSF1 required to
achieve complete inhibition of splicing was almost iden-
tical (6 pmoles per microliter of extract). A similar quan-
tity of SRp30 was used to restore full splicing activity,
suggesting that RSF1 might proceed by competing with
SR proteins for the same function.
RSF1 prevents E-complex formation in vitro
The SR proteins are known to promote the earliest stages
of the spliceosome assembly involving the formation of
the E (for early) or commitment complex, in which the 58
splice site is recognized by U1 snRNP and the 38 splice
Figure 1. Schematic representation of the re-
combinant proteins used in this study (Left).
RNA recognition motifs (gray), GRS and RS
domains (white), and hexahistidine tags
(black) are boxed. GST fusion proteins were
expressed and purified as described (Materials
and Methods). SRp30 protein was purified
from calf thymus as described (Zahler et al.
1992). Around 1 µg of each purified protein
was analyzed on a 12% SDS–polyacrylamide
gel and stained with Coomassie blue (right).
Markers 70 K, A, B, B8, and D refer to U1
snRNP proteins. (M) Molecular weight mark-
ers.
Figure 2. The effect of GST–RSF1 on pre-mRNA splicing in
vitro. (A) b-3A splicing inhibition by GST–RSF1 is relieved by
purified SRp30. 32P-Labeled b-3A pre-mRNA (50 pmoles, lanes
1,13) were incubated in HeLa cell nuclear extract (NE) under
splicing conditions without (lanes 2,14) or with 18 or 36 pmoles
of the indicated recombinant proteins (lanes 3–12). HeLa
nuclear extract inhibited by 36 pmoles of GST–RSF1 (lane 15)
was complemented with 15 or 30 pmoles of purified SRp30
(lanes 16,17). Splicing products (depicted at right) were analyzed
on a 7% denaturing polyacrylamide gel and revealed by autora-
diography. (B) Splicing reactions (lanes 1–11) were performed as
in A (lanes 1–4 and 11–17, respectively) using a b-globin pre-
mRNA lacking the RSF1 high-affinity binding sites.
Labourier et al.
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site by binding of U2AF65 at the pyrimidine tract (Ruskin
et al. 1988; Zamore and Green 1989; Jamison et al. 1992;
Michaud and Reed 1993; Staknis and Reed 1994; Reed
1996). Given that RSF1 acts as a splicing repressor of
several reporter pre-mRNAs, including AdML (data not
shown), a model pre-mRNA derived from the adenovirus
major late-transcription unit, we tested whether it could
interfere with the formation of E complex and thereby
mediate splicing inhibition. Previous studies demon-
strated that AdML is assembled into splicing complexes
more efficiently than b-globin (Michaud and Reed 1991);
we therefore used this substrate to perform E-complex
assembly assays. HeLa cell nuclear extracts comple-
mented with either purified SRp30 or GST–RSF1 were
incubated with 32P-labeled AdML (Michaud and Reed
1991, 1993) and assembled RNP complexes were frac-
tionated by gel filtration. As shown in Figure 3, in con-
trast to SRp30, which enhanced the level of E-complex
assembly (Fig. 3, cf. I and III). GST–RSF1 blocked the
formation of this complex completely (panels I and II).
However, full E-complex assembly could be restored
upon addition of competing amounts of purified SRp30
to RSF1-inhibited nuclear extract (data not shown), dem-
onstrating that the inhibition of splicing by RSF1 was at
the level of E-complex assembly.
To evaluate the effects of RSF1 on 58 or 38 splice-site
selection, specific complexes were assembled indepen-
dently on RNAs containing only a 38 or 58 splice site,
respectively, as described (Michaud and Reed 1993). In
agreement with previous studies, both AdML 58 and 38
half substrates (panels IV and VI, respectively) gave rise
to discrete peaks in the position of E complex when in-
cubated with HeLa nuclear extract. Although substantial
E complex on the 38 splice site was still detected in ex-
tracts complemented with GST–RSF1 (panel VII, 3.5
pmoles/microliter of extract), little or no E complex was
formed on the 58 splice site (panel V). Inhibition of E
complex formation on the 58 splice site is unlikely to
result from unspecific binding of GST–RSF1 to AdML 58
half substrate because neither truncated versions of
RSF1 nor GST–RBP1 had the same effect (data not
shown). We conclude that RSF1 probably prevents the
stable binding of factor(s) to the 58 splice site but has
only slight effect on the binding of factor(s) to the 38
splice site.
RSF1 impedes stable binding of U1 snRNP at the 58
splice site
The prototypical SR protein SF2/ASF was shown previ-
ously to cooperate with the U1 snRNP particle in form-
ing a stable complex at the 58 splice site of the model
pre-mRNA PIP7.A (Kohtz et al. 1994). We therefore
tested whether RSF1 could destabilize the binding of U1
snRNP to the 58 splice site. Different combinations of
recombinant SF2/ASF, purified U1 snRNP (Fig. 1, lanes
7,11) and GST–RSF1 were incubated with either 32P-la-
beled PIP7.A or PIP758AU, a mutant version that is iden-
tical to PIP7.A, except that the invariant GU dinucleo-
tide at the 58 splice site is changed to AU (Kohtz et al.
1994; Jamison et al. 1995). The mixes were then analyzed
by native gel electrophoresis to resolve the U1 snRNP-
containing complexes from the free probe. No complex
was detected with the mutated substrate (Fig. 4, lane 3),
indicating that an intact, functional 58 splice site is re-
quired for formation of U1 snRNP–SF2/ASF–pre-mRNA
complex. In agreement with previous findings (Kohtz et
al. 1994), U1 snRNP alone gave rise to low levels of U1
snRNP–pre-mRNA complex formation (lane 2), whereas
when both U1 snRNP and SF2/ASF were incubated with
the pre-mRNA a strong complex was detected (lane 5).
Interestingly, GST–RSF1 had no effect on the weak bind-
ing of U1 snRNP to the pre-mRNA (lane 15) but im-
paired the formation of U1 snRNP–SF2/ASF–pre-mRNA
Figure 3. The effect of GST–RSF1 on E-complex assembly.
32P-Labeled AdML pre-mRNA (I–III), truncated Ad58 (IV,V),
or Ad38 (VI,VII) pre-mRNAs were incubated in HeLa nuclear
extracts (I,IV,VI), or HeLa nuclear extracts supplemented
with purified SRp30 (III; 210 pmoles) or GST–RSF1 (II,V,VII;
260 pmoles) in the absence of ATP. Complexes were then
fractionated by gel filtration. The peaks containing E or H
complexes and free RNA are indicated.
RSF1, a Drosophila antagonist of SR proteins
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ternary complex dramatically (lanes 7–9). The GRS do-
main of RSF1 was required to mediate inhibition, as a
GRS-truncated version of RSF1 was inactive (lane 10).
The GST–RSF1 inhibition was dose dependent; it was
almost complete when the ratio between RSF1 and SF2/
ASF was nearly 1:1 (lane 9). The possibility that inhibi-
tion was caused by unspecific binding of GST–RSF1 to
RNA can be ruled out, because GST alone (lane 11), or
GST–RSF1DC (lane 10) had negligible effects on ternary
complex formation. Furthermore, preassembled ternary
complex was refractory to inhibition by GST–RSF1 (cf.
lanes 16 and 18), suggesting a direct interaction between
RSF1 and U1 snRNP and/or SF2/ASF.
The GRS domain of RSF1 interacts with the RS
domain of SF2/ASF
The RS domain of SF2/ASF is required for the direct
interaction between the latter and the 70K U1 snRNP-
specific protein (U1–70K) and likely mediates the stable
binding of U1 snRNP to the 58 splice site. Because this
domain is involved in various selective protein–protein
contacts (Wu and Maniatis 1993; Kohtz et al. 1994;
Lynch and Maniatis 1995, 1996), we asked whether spe-
cific inhibition of 58 splice-site recognition could result
from specific binding of this domain with a defined do-
main of RSF1. To test this, GST–RSF1 or GST–RSF1DC
proteins were immobilized on glutathione–Sepharose
beads and incubated with a purified His-tagged RS do-
main of SF2/ASF (Fig. 1, lane 9). Strikingly, the RS do-
main of SF2/ASF quantitatively bound to GST–RSF1
(Fig. 5A, lane 4). In contrast, only a background level of
binding, similar to that for beads alone, was detected
with GST–RSF1DC (Fig. 5A, cf. lanes 5 and 6), suggesting
that the GRS domain of RSF1 is essential for binding.
Interestingly, a purified His-tagged GRS domain (Fig. 1,
lane 10) exhibited the same chromatographic behavior as
the RS domain (Fig. 5A, lanes 1 and 2), indicating that
Figure 4. The effect of GST–RSF1 on U1 snRNP binding to the
58 splice site. U1 snRNP–SF2/ASF–pre-mRNA complex forma-
tion assays were performed as described previously (Kohtz et al.
1994) in 10-µl reactions containing 1.7 pmole of U1 snRNP
(lanes 2,3,5,6–12,15–18), 3 pmoles of SF2/ASF (lanes 4–11,
14,16–18), 0.67 pmole (lane 7), 1.35 pmole (lane 8), or 2.7 pmoles
(lanes 9, 13–15,17,18) of GST–RSF1, 2.7 pmoles of GST–
RSF1DC (lane 10), 2.7 pmoles of GST (lane 11), and 1.5 fmole of
either 32P-Labeled PIP7.A (lanes 1,2,4,5,7–18) or PIP758AU pre-
mRNAs (lanes 3,6). GST fusion proteins and SF2/ASF were
added to the reaction mixture at the same time except for the
postcompetition assay (lane 18) in which GST–RSF1 was added
after U1 snRNP and incubated for additional 5 min at 30°C.
Figure 5. Physical interaction between the GRS domain of RSF1 and the RS domain of SF2/ASF. (A) GST binding assays. Purified
RSF1 GRS (lanes 1–3) and SF2/ASF RS (lanes 4–6) proteins were incubated with immobilized GST–RSF1 (lanes 1,4), GST–RSF1DC
(lanes 2,5) or glutathione–Sepharose beads alone (lanes 3,6). Bound proteins were eluted, analyzed on 12% SDS–polyacrylamide gels,
and stained with Coomassie blue. (B) Far-Western analysis. The indicated proteins were separated on a 12% SDS–polycrylamide gel,
transferred to nitrocellulose, renatured, and probed with 32P-labeled SF2/ASF (lanes 1–9) or GST–RSF1 (lanes 10–16).
Labourier et al.
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RSF1 not only interacts with SF2/ASF but also with it-
self. Given that the GRS domain is soluble at high con-
centrations (10 mg/ml), it seems unlikely that its inter-
action with itself or with the RS domain could be the
result of nonspecific aggregation.
To confirm the specificity of these protein–protein in-
teractions independently and to establish whether RSF1
could bind U1–70K, we employed Far-Western blotting
(Wu and Maniatis 1993; Kohtz et al. 1994), which has
been used successfully to show specific interactions be-
tween members of the SR protein family and other splic-
ing factors. After SDS-PAGE analysis, purified proteins
were transferred to filters, renatured, and probed with
either 32P-labeled SF2/ASF or GST–RSF1 (Fig. 5B). The
specificity of binding of modified SF2/ASF or RSF1 was
confirmed by their ability to bind themselves (lanes
1,12), but not to truncated derivatives deleted for the RS
(lanes 2,10) or GRS (lanes 5,13) domains, respectively.
Although, both probes cross-reacted with immobilized
SF2/ASF (lanes 1,9) and GST–RSF1 (lanes 4,12), as well
as GST–RBP1 (lanes 7,15), only labeled SF2/ASF (lane 8),
but not GST–RSF1 (lane 16), could decorate the U1–70K
band, showing that no binding could occur between
RSF1 and U1–70K. Failure to detect significant recogni-
tion between RSF1 and U1–70K provides further evi-
dence that the observed interaction between GRS and RS
domains is specific. Such an interaction is likely to com-
pete with that occurring between SF2/ASF and U1–70K,
thereby interfering with the formation of a stable com-
plex at the 58 splice site.
RSF1 functionally antagonizes the SR protein B52
in living flies
Previous work has shown that overexpressing B52 pro-
tein, also called SRp55, in a number of cell types affects
development and survival of Drosophila dramatically
(Kraus and Lis 1994) and that the B52/SRp55 protein can,
in vitro, regulate alternative 58 splice-site choice in a
concentration-dependent manner. Hence, the ratio of
B52/SRp55 to other splicing factors in vivo might be an
important means of regulating alternative splicing. Be-
cause developmental Northern blot (RNA) revealed that
the RSF1 gene, like the B52/SRp55 gene (Champlin et al.
1991), is expressed throughout development (Fig. 6, lanes
1–11) and RSF1 interacts in vitro with B52/SRp55 (Fig.
5B, lane 18), we considered the possibility that RSF1 is
such a splicing factor. Therefore, we assessed whether
RSF1 might functionally antagonize the SR ptotein B52/
SRp55 in a living animal. The GAL4/UAS binary expres-
sion system (Brand et al. 1994) was used to drive pro-
longed high levels of expression of both RSF1 and B52/
SRp55 in a tissue-specific fashion. To this end, the wild-
type RSF1 cDNA was placed within a P-element
transposon under transcriptional control of the yeast
GAL4-responding upstream activating sequence (UAS–
RSF1 element) and 15 independent UAS–RSF1 trans-
genic lines were established, using standard procedures
(Spradling and Rubin 1982). Transgenic flies carrying
UAS–RSF1 and/or UAS–B52 (Kraus and Lis 1994) ele-
ments were mated to flies that express the yeast tran-
scriptional activator GAL4 in a cell- or tissue-specific
fashion to drive strong expression of RSF1 and/or B52/
SRp55. To examine the tissue-specific expression of
GAL4 in each cross, lines carrying GAL4 elements were
crossed to a transgenic line carrying the E. coli b-galac-
tosidase-encoding gene under the control of the GAL4
activator (UAS–lacZ; Brand et al. 1994).
Using the GMR–GAL4 (for glass multimer reporter;
Freeman 1996) line we directed expression and activity
of RSF1 to photoreceptor cells of the developing eye.
Adult progeny consistently showed retinal defects, the
severity of which depended on the UAS–RSF1 transgenic
line employed. Relatively weak defects of retinal devel-
opment were observed with UAS–RSF1 lines 5 and 6
(Fig. 7B, cf. b and c, respectively, with a) compared to line
3 (Fig 7B, d) which gave rise to eyeless adults. Further-
more, most progeny of lines 5 and 6 were viable (see
Table 1) but line 3 offspring had a strongly decreased
viability ( ~ 20%). The latter observation suggests that the
GMR element is not entirely eye specific, and that RSF1
overproduction in tissues other than the eye is lethal.
Although it is difficult to determine the direct cause of
this lethality, it might reflect differences in the levels of
RSF1 ectopic expression owing to different UAS–RSF1
chromosomal insertions. On increasing the dosage of
UAS–RSF1 elements (genotypes GMR–GAL4/+; UAS–
RSF13/UAS–RSF16, and GMR–GAL4/+; UAS–RSF16/
UAS–RSF16) no viable offspring were observed (Table 1).
Furthermore, embryonic lethality was also observed
when high uniform expression of RSF1 was driven by
GAL4 under the constitutive daughterless (da) enhancer
(data not shown). Therefore, a correlation exists between
the level of RSF1 overexpression in various tissues and
lethality.
Another fully penetrant phenotype was observed in
the progeny of crosses between UAS–RSF15 and sca–
Figure 6. RSF1 mRNA expression during Drosophila develop-
ment. Approximately 2 µg of poly(A)+ RNA isolated from whole
organisms of indicated stages was separated by electrophoresis
in a 1% agarose–formaldehyde gel. The size-fractionated RNAs
were then blotted to a nylon membrane and probed with a ra-
diolabeled full-length cDNA insert. The blot was re-hybridized
with a radioactive probe for the rpL17A ribosomal protein gene
(Noselli and Vincent 1992) as a loading control to estimate the
relative amount of RNA loaded in each lane.
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GAL4, a GAL4-expressing line that accumulates GAL4
activator in precursor cells of all sensory organs owing to
an imaginal disc-specific enhancer of the scabrous gene
(Y.N. Jan, unpubl.; see Fig. 8A for structure). The adult
progeny displayed complete loss of all bristles (Fig. 8B, cf.
a and c). Increasing temperature appears to enhance the
transcriptional activation by GAL4 in Drosophila (Brand
et al. 1994). On elevating the level of overexpression of
RSF1 by raising the offspring at higher temperatures
(22°C, 25°C, or 28°C), the same phenotypes were aggra-
vated (data not shown). Note also that mating sca–GAL4
with UAS–RSF16 gave rise to progeny with late pupal
lethality (Table 1).
A previous study concluded that overexpressing B52/
SRp55 protein provokes a dominant lethality (Kraus and
Lis 1994). Hence, we decided to examine the phenotypic
consequences of overexpressing B52/SRp55 under the
same genetic background used for RSF1 overproduction.
Among progeny raised at 22°C, no adult female was ob-
served when B52/SRp55 overexpression was driven by
Figure 7. RSF1 overexpression in differen-
tiating photoreceptor cells leads to adult
eye defects, and restores developmental ab-
normalities caused by B52/SRp55 overex-
pression in the same tissue. (A) Virgin fe-
male flies carrying a P-element insert in
which the GAL4 coding sequence was
placed under the control of five glass bind-
ing sites (GMR enhancer) were mated to
male flies carrying a single UAS–B52 or
UAS–RSF1
3,5, or 6
, element or a combination
of both. (B) Stereomicroscope views of adult
compound eyes. The following genotypes
are shown: GMR–GAL4/+; (a) UAS–lacZ/+,
(b) GMR–GAL4/UAS–RSF15, (c) GMR–
GAL4/+; UAS–RSF16/+; (d) GMR–GAL4/+;
UAS–RSF13/+, (e) GMR–GAL4/UAS–B52,
(f) GMR–GAL4/UAS–B52; UAS–RSF13/+.
The control fly, overexpressed the E. coli
b-galactosidase (a) from an UAS–lacZ con-
struct line (Brand et al. 1994). All progeny
were raised at 22°C. Overexpression of
RSF1 in the developing retina results in a
decrease of adult eye size that can be mod-
erate (b,c) or severe (d) depending on the site
of chromosomal integration of the trans-
gene. (C) Detection of RSF1 and B52 trans-
gene expression in single and double insert
lines. (I) Determination of semiquantitative
conditions to amplify UAS–RSF1, UAS–
B52, and the Drosophila retrotransposon
copia mRNAs by RT–PCR. For each experi-
ment, 1⁄40 (lanes 1,4,7), 1⁄20 (2,5,8) or 1⁄10
(3,6,9) of the RT reaction performed with 5
µg of total RNAs, from larvae overexpress-
ing both UAS–RSF1 and UAS–B52, were
used for PCR amplification with the appro-
priate pair of specific oligonucleotides (Ma-
terials and Methods). Amplified fragments
(423, 355, or 228 bp for UAS–RSF1, UAS–
B52, and copia, respectively) were revealed
by autoradiography. (M) Molecular weight
markers. (II) PCR products obtained with
1⁄10 of RT reactions performed with total
RNAs from control larvae (lane 1), larvae
overexpressing UAS–RSF1 (lane 2), UAS–
B52 (lane 3), or both transgenes (lane 4). (III)
Total proteins from the same transgenic lar-
vae in II, (lanes 1–4) or from HeLa nuclear
extract (lane 5) were subjected to Western
blot analysis using the monoclonal anti-
body mAb104. SR protein species are indi-
cated at right.
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GMR–GAL4 (all females died as late pupae) and the rare
eclosed males (<1% of late male pupae) exhibited a fully
penetrant eye phenotype distinct from those observed
among the offspring derived from crosses with the vari-
ous UAS–RSF1 lines (Fig. 7B; Table 1). However, the
progeny from the crosses of flies expressing GAL4 from
sca enhancers to flies carrying the UAS–B52 element
was viable but fails to develop bristles (Fig. 8B; Table 1).
Except for a lower viability, this developmental abnor-
mality was very similar to the one caused by RSF1 over-
expression driven by sca–GAL4 enhancer (Table 1, UAS–
RSF15/+; sca–GAL4/+; Fig. 8B, cf. b and c). Taken to-
gether, these data strongly indicate that a normal level of
RSF1 or B52/SRp55 protein is critical for viability and
normal development of most organs.
Our biochemical data provided evidence for a func-
tional, stoichiometric antagonism between recombinant
RSF1 and SR proteins purified from HeLa cells (see
above). To test this model in vivo, we asked whether
overproduction of RSF1 can rescue some or all of the
defects caused by B52/SRp55 overexpression. Transgenic
flies carrying both a UAS–B52 and a UAS–RSF1 element
were crossed with the GMR–GAL4 transgenic flies. In-
terestingly, adult progeny of both sexes were obtained,
implying that overexpression of RSF1 protein can over-
come at least the female lethality and some developmen-
tal defects caused by the overexpression of B52/SRp55
protein. A trivial GAL4 dosage effect owing to the pres-
ence of two copies of the UAS promoter can be ruled out,
because two copies of the UAS–RSF1 elements lead to
more deleterious developmental defects than one copy
alone (Table 1). The possibility that the overexpression
of RSF1 reduces the overexpression of B52/SRp55 can
also be discounted, because quantitative reverse tran-
scription (RT)-PCR showed that UAS–B52 mRNA lev-
els, determined at the third-instar larvae, was the same in
the progeny overexpressing B52/SRp55 as in the progeny
overexpressing B52/SRp55 and RSF1 (Fig. 7C, panel II, cf.
lanes 3 and 4). Similar UAS–RSF1 mRNA levels were
also observed between progeny overexpressing RSF1 and
progeny overexpressing RSF1 and B52/SRp55 (Fig. 7C,
panel II, cf. lanes 2 and 4). Furthermore, Western blot
analysis using a monoclonal antibody (mAb104) that rec-
ognizes several SR protein species (Zahler et al. 1992),
defined as SRp20, SRp30a-SRp30b, SRp40, SRp55 (B52),
and SRp75, depending on their apparent molecular
weight in SDS gels (Fig. 7C, panel III, lane 5), detected a
strong band at the level of B52/SRp55 in progeny over-
expressing B52/SRp55 (Fig. 7C, panel III, lanes 3,4) but
only very little in the progeny that do not (Fig. 7C, panel
III, lanes 1,2). The signal of B52/SRp55 did not diminish
following overexpression of RSF1 (Fig. 7C, panel III, cf.
lanes 3 and 4), confirming that RSF1 has no effect on the
expression of B52/SRp55 at the protein level. Given that
Table 1. Phenotypes of progeny from crosses between UAS–RSF1 and/or UAS–B52 transgenic lines and GAL4 lines
Genotype of examined progenya
Temperature
(°C) Observed phenotypes
UAS–RSF13, 5, or 6/+ 18 or 22 adults without apparent abnormalities
UAS–B52/+ 18 or 22 adults without apparent abnormalities
any GAL4 driver/+ 18 or 22 adults without apparent abnormalities
GMR–GAL4/+; UAS–lacZ/+ 22 adults without apparent abnormalities
UAS–lacZ/sca–GAL4 18 adults without apparent abnormalities
Transgenic flies overexpressing RSF1
GMR–GAL4/+; UAS–RSF13/+ 22 some adults without retina (~ 20% viability)
GMR–GAL4/UAS–RSF1 5 22 adults with weak retina defects (100% viability)
GMR–GAL4/+; UAS–RSF16/+ 22 adults with weak retina defects (~ 95% viability)
GMR–GAL4/+; UAS–RSF13/UAS–RSF16 22 larval and pupal lethality; no adults
GMR–GAL4/+; UAS–RSF16/UAS–RSF16 22 pupal semilethality. Rare adults without retina (<1% viability)
UAS–RSF15/+; sca–GAL4/+ 18 bristleless adults (~ 50% viability)
UAS–RSF16/sca–GAL4 18 late pupal stage lethality; no adults
Transgenic flies overexpressing B52
GMR–GAL4/UAS–B52 22 no adult females; rare adult males with weak retina defects
(<1% viability)
UAS–B52/+; sca–GAL4/+ 18 bristleless adults (>90% viability)
Transgenic flies overexpressing RSF1 and B52
GMR–GAL4/UAS–B52; UAS–RSF16/+ 22 adults of both sexes with weak retina defects (~ 90% viability)
GMR–GAL4/UAS–B52; UAS–RSF13/+ 22 adults of both sexes with strong retina defects (~ 50% viability)
UAS–B52/+; sca–GAL4/UAS–RSF16 18 adults with a complete (~ 10%) or partial set of sensory bristles
(~ 80% viability)
UAS–B52 is a second chromosome insert line from John Lis and colleagues (Kraus and Lis 1994). Most cell lines were provided by the
Bloomington Stock Center. The third chromosome sca–GAL4 line was provided by M. Vervoord. The UAS–lacZ insert line is
described in Brand et al. (1994).
aMore than 200 progeny were examined.
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mAb104 recognized a phosphoepitope (Roth et al. 1991),
it is likely that overexpressed B52/SRp55 is modified by
phosphorylation. Thus the rescue of the lethal pheno-
type could be explained by opposite function of RSF1 and
B52/SRp55.
We also analyzed this opposite function when overex-
pression of RSF1 and B52/SRp55 was driven in another
tissue. Although, overexpression of RSF1 under sca–
GAL4 enhancer (UAS–RSF16/sca–GAL4) leads to no
adults because of late-purpal stage lethality and overex-
pression of B52/SRp55 (UAS–B52/+; sca–GAL4/+) leads
to bristless adults, the progeny of crosses between UAS–
B52 + UAS–RSF16 double element lines and sca–GAL4
transgenic flies were viable and had a complete ( ~ 10% of
the eclosed offspring) or a partial (90% of the eclosed
offspring) stereotyped set of apparently normal sensory
bristles (Table 1; Fig. 8B, d). Failure to revert complete
bristles phenotypes of all progeny flies (~ 10% had the
wild-type phenotype) strongly suggests that the ratio of
RSF1 and B52/SRp55 (and/or other SR proteins) may be
critical for the normal development of specific organs.
Thus, as expected by our model, these in vivo experi-
ments did not reveal functional synergy but rather an
antagonism between RSF1 and B52/SRp55; the detri-
mental effects caused by accumulation of one protein
could be partially or fully suppressed by joint accumula-
tion of the other.
Discussion
RSF1 is a novel splicing regulator that selectively coun-
teracts SR protein function at the earliest steps of spli-
ceosome assembly, preventing the stable binding of U1
snRNP to pre-mRNA, and thus inactivating 58 splice-site
selection. Such an activity is likely to be relevant in vivo
to prevent inappropriate SR protein-dependent activa-
tion of cryptic and/or weak 58 splice sites found near
exonic enhancer sequences (Watakabe et al. 1993; Elrick
et al. 1998). This fits nicely with the ability of RSF1 to
bind enhancer splicing sequences through its RRM (E.
Labourier, E. Allemand, S. Brand, M. Fostier, J. Tazi, and
H.-M. Bourbon, unpubl.) and to interact via its GRS do-
main with the RS domain of SR proteins, thereby im-
pairing the formation of productive splicing complexes.
The observation that RSF1 and SR proteins colocalize
in the same nuclear regions (data not shown) could be
attributed to their participation in similar nuclear
events. We present evidence that RSF1 can interact di-
rectly with SF2/ASF and that the GRS domain of the
former and the RS domain of the latter are required for
this interaction. This protein-protein interaction is
likely to compete with those occurring between SR pro-
teins and constitutive factors involved in the selection of
alternative splice sites. Indeed, SR proteins have been
shown to promote the binding of U1 snRNP to the 58
splice site (Eperon et al. 1993; Kohtz et al. 1994; Staknis
and Reed 1994; Zahler and Roth 1995), most likely
through specific protein–protein interactions between
SR proteins and U1–70K (Wu and Maniatis 1993; Kohtz
et al. 1994). At least in vitro, we show that RSF1 prevents
cooperative interaction between SF2/ASF and U1–sn-
RNP 70K protein and thus interferes with the stable
binding of U1 snRNP at the 58 splice site. RSF1 may have
emerged during evolution as a dominant-negative SR
protein that is able to bind negative and/or positive cis-
acting regulatory sequences preventing activation of
nearby weak splice sites. This antagonistic activity dif-
fers significantly of that of hnRNP A1 whose ratio to
SF2/ASF specifies the selection of alternative 58 splice
sites (Mayeda and Krainer 1992) or mutually exclusive
exons and modulates exon skipping and inclusion (May-
eda et al. 1993). Although the mechanisms by which
hnRNP A1 and SF2/ASF modulate the use of alternative
58 splice sites remain poorly understood, it might in-
volve an intrinsic hnRNP A1 activity that can facilitate
the rapid annealing of complementary RNA molecules
that is, between the 58 end of U1 snRNA and 58 splice
site, as well as specific recognition of pre-mRNA se-
Figure 8. RSF1 functionally antagonizes B52/SRp55 in joint
overexpression. (A) Virgin female flies carrying a P element, in
which the GAL4-coding sequence was placed under the control
of an imaginal disc-specific scabrous (sca) enhancer, were mated
to male flies carrying a single UAS–B52 or UAS–RSF15 or 6 ele-
ment or a combination of both. (B) Stereomicroscope views of
nota of flies carrying the following genotypes: sca–GAL4/UAS–
lacZ (a), UAS–B52/+; sca–GAL4/+ (b), UAS–RSF15/+; sca–
GAL4/+ (c), and UAS–B52/+; sca–GAL4/UAS–RSF16 (d). All
progeny were raised at 18°C.
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quences via the RRM domains of hnRNP A1 (Mayeda et
al. 1994). RSF1 also requires its RRM domain for activity
and this domain might even recognize the same se-
quence as SR proteins but its GRS domain, shown to be
essential for splicing repression in vitro, represents a
new module acting against the RS domain that has been
shown to function as activator of pre-mRNA splicing
(Graveley and Maniatis 1998). The modular structure of
RSF1 and SR proteins strengthen the correlation be-
tween splicing and transcription factors, proposed by
Graveley and Maniatis, as both factors contain separable
nucleic acid binding and activation or repression do-
mains.
In a given tissue small changes in the RSF1/SR equi-
librium could have profound effects on binding site oc-
cupancy by either factor and thereby regulate splice-site
selection. In this context, it may be relevant that exonic
purine-rich sequences have been observed near weak
splice sites of many cellular and viral pre-mRNAs that
are subject to alternative splicing (Katz and Skalka 1990;
Lavigueur et al. 1993; Sun et al. 1993b; Watakabe et al.
1993; Xu et al. 1993; Caputi et al. 1994; Dirksen et al.
1995; Ramchatesingh et al. 1995; Staffa and Cochrane
1995; Staffa et al. 1997). Although in most cases, these
elements stimulate splicing of the upstream intron or
inclusion of an internal exon, there are exceptions to this
rule in which purine-rich elements have been shown to
serve as splicing repressors (Kanopka et al. 1996; Mc-
Nally and McNally 1996). The binding of RSF1 to ESE (E.
Labourier, E. Allemand, S. Brand, M. Fostier, J. Tazi, and
H.-M. Bourbon, unpubl.) could be a way to mediate splic-
ing repression to prevent activation of cryptic splice sites
within large exons. In agreement with this hypothesis, it
has been shown recently that RSFc, a protein in the dip-
teran Chironomus tentans homologous to RSF1, binds
extensively to newly transcribed BR1 and BR2 pre-
mRNAs, which contain a huge exon 4 of 30–35 kb but
much less to the BR3 pre-mRNA, which largely consists
of intron sequences (L. Wieslander, pers. comm.).
In vivo experiments are expected to illuminate our
findings to provide a rationale to explain how alternative
fates of a wide variety of pre-mRNAs can be controlled
by a small set of evolutionarily conserved antagonistic
sequence-specific splicing factors whose levels or activi-
ties may be regulated according to tissue or developmen-
tal stages. Consistently, targeted expression in Dro-
sophila of transgenes encoding either the SR protein
B52/SRp55 or RSF1 led to pronounced deleterious effects
on development (Kraus and Lis 1994; this work). Differ-
ent severities of phenotype were observed depending on
levels of transgene expression, both for B52/SRp55 and
for RSF1 (Table 1). Strikingly the effects of the proteins
depend on their relative levels as when both proteins
were overexpressed in the same tissue the mutant phe-
notypes were reverted partially or completely. For in-
stance, >90% of progeny from crosses between GMR–
GAL4 and UAS–RSF13 or UAS–B52 lines were unable to
eclose (Table 1). In sharp contrast, the crosses of trans-
genic flies carrying both a UAS–B52 and an UAS–RSF13
element with GMR–GAL4 line led to 50% viability. Fur-
thermore, overexpression of B52/SRp55 restored viabil-
ity to flies overexpressing RSF1 under the control of an-
other tissue-specific enhancer, the imaginal disc-specific
enhancer of the scabrous gene (compare UAS–RSF16/
sca–GAL4 and UAS–B52/+; sca–GAL4/+ to UAS–B52/
+; sca–GAL4/UAS–RSF16), implying that B52/SRp55
could have opposing effect to RSF1 in different tissues.
These phenotypes cannot be attributed to low levels of
expression of either RSF1 or B52/SRp55 mRNAs in the
progeny of double-insert lines compared to the progeny
of single-insert lines, as these levels were the same (Fig.
7C, panels II, III). Instead, these results support a model
in which RSF1 and RSF1-related proteins function as SR-
protein antagonists. At this time, we cannot prove that
this antagonistic effect is actually a result of competition
between a splicing repressor and a splicing activator for
the selection of correct splice sites in vivo, although the
large body of in vitro work makes this a likely conclu-
sion. By preventing weak and/or cryptic splice sites ac-
tivation by high levels of SR proteins, RSF1 is expected
to restore correct splicing of essential genes for Dro-
sophila development. Therefore, our in vivo work paves
the way toward a molecular genetic analysis of the bio-
logical role of RSF1, which might allow to uncover fac-
tors modifying the activity of RSF1 and SR proteins.
Materials and methods
Oligonucleotides
The sequences of the synthetic oligonucleotides (Isoprim SA,
Toulouse, France) used in this study as cloning adapters or PCR
primers are (sequence is given 58 fi 38) 21Gex, GCAAGCTTG-
GTGATCAGCGCGGGACAC; F47, CGCCAGGGTTTTCCC-
AGTCACGAC; ADA1, GATCCCCGGTCAGAATTCAAGCTT-
ATCGATGAGCTCT; ADA2, AGCT-AGAGCTCATCGATAA-
GCTTGAATTCTGACCGGG; 21H1, CTAGATTAGTTGGCG-
CTGCTGTGATGATGATGATGATGGCTGCTGCCGAAT;
21H2, CGATTCGGCAGCAGCCATCATCATCATCATCACA-
GCAGCGCGCCAACTAAT; 21ADA1,GATCTCAAAAGGGC-
GGCCACGCCAT; 21ADA2, CGATGGCGTGGCCGCCCTT-
TTGA; 1RBP1, CTTGGATCGCAATCGACATAGG;2RBP1, CA-
CATATGCCGCGATATAGGGAG; HB2T1, GATCCC-GTCGT-
TGTCGTCGTTGTCGTCGTTGCAAGGGT; HB2T2,CTACCC-
TTGCAACGACGACAACGACGACAACGACGG; UAS1, GT-
AACCAGCAACCAAGTAAATCAAC;21F2, TCCCCCTCCAG-
ATCATCCTT; B52A, AACAACCACACCGTTCGCCAAGC;
copiaS, GGGCTCTTTTAGCCGAGCAAG; and copiaA, CGCA-
GCGCCAGTTGCGACG.
Recombinant proteins, plasmids, and purification
The IPTG-controlled GST expression system (Smith and
Johnson 1988) was used to produce RSF1 fusion proteins. A
1.1-kb HindIII–XbaI fragment from pNB21/5.3R [a RSF1 cDNA
insert cloned into the pNB40 vector (Brand et al. 1995)] was
subcloned into pBluescript II (KS−) between the HindIII and
XbaI sites, to yield the p11HX1 plasmid. The p11HX1 plasmid
was in turn used as a template in a PCR with Taq DNA poly-
merase (Boehringer Mannheim) to amplify the entire RSF1 open
reading frame (ORF). A HindIII site was introduced at the 58 end
by using the 21Gex oligonucleotide and the pBluescript se-
quencing primer F47. Amplified DNA was cut with HindIII and
SacI and inserted into the bacterial GST fusion protein expres-
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sion vector pHBGex between the unique HindIII and SacI sites,
to yield the pGex21 expression plasmid. The pHBGex plasmid
was derived from pGexA (Valle et al. 1993) by inserting a Bam-
HI–HindIII adaptor made of the two complementary oligo-
nucleotides ADA1 and ADA2 between the BamHI and HindIII
sites (note that the original HindIII site has been destroyed). The
RSF1 ORF was entirely sequenced to verify its integrity by using
a set of synthetic oligonucleotides. To allow for expression of a
doubly tagged fusion protein (termed GST–RSF1) with a hexa-
histidine-based carboxy-terminal affinity tag, a ClaI–XbaI adap-
tor, made of the two complementary oligonucleotides 21H1 and
21H2, was inserted between the unique ClaI and XbaI sites of
pGex21, to yield the pGex21HP1 plasmid. To allow for expres-
sion of a doubly tagged fusion protein (termed GST–RSF1DC)
with most of the GRS domain deleted, a BglII–ClaI adaptor
made of the two complementary oligonucleotides 21ADA1 and
21ADA2, was introduced between the unique BglII and ClaI
sites of pGex21HP1 (substituting a 360-bp fragment), to yield
the pGex21HPN1 plasmid. To allow for expression of a doubly
tagged fusion protein (termed GST–RSF1DN) with amino-termi-
nal RRM-containing domain deleted, pGex21HP1 plasmid
DNA was cut with EcoRI and BglII and religated (eliminating a
235-bp fragment) after end filling with the Klenow fragment of
E. coli DNA polymerase I and dNTPs, to yield the pGex21HPC1
plasmid. The GST-RBP1 fusion was produced from the
pGexRBP1 plasmid, which was constructed as follows. The en-
tire coding sequence of RBP1 was PCR amplified from cDNA
prepared from poly(A)+ RNAs extracted from 4- to 8-hr-stage
embryos, by using two specific oligonucleotides, termed 1RBP1
and 2RBP1. The resulting 520-bp PCR product was cut with
NdeI and EcoRI and inserted into a derivative of pHBGex (H.-M.
Bourbon, unpubl.). The RBP1 ORF was entirely sequenced to
verify its integrity with respect to the original sequence.
To allow for expression of an hexahistidine-tagged version of
the GRS domain of RSF1 (termed RSF1 GRS protein) a 360-bp
NcoI–XbaI fragment from the pGex21HP1 plasmid was inserted
into the T7-based expression vector pET-14b (Novagen) cut
with NcoI and NheI.
To obtain hexahistidine-tagged SF2/ASF proteins, wild-type
or truncated versions of SF2/ASF cDNA (provided by J. Manley,
Columbia University, New York, NY) were fused in-frame by
PCR amplification in pTrcHisA (Invitrogen), using oligonucleo-
tides whose sequences are available upon request (Labourier et
al. 1998).
To overexpress GST fusion proteins, BL21 cells (Novagen)
freshly transformed with pGex21HP1, pGex21HPN1,
pGex21HPC1, pGexRBP1, or pHBGex (as a control) were grown
under strong agitation into 2TY medium (16 grams/liter tryp-
tone, 10 grams/liter yeast extract and 5 grams/liter NaCl; pH
was adjusted to 7 with NaOH) at 37°C to an absorbance of 0.8 at
600 nm in the presence of 100 µg/ml ampicillin. Isopropyl-b-d-
THIOGALACTOPYRANOSIDE (IPTG) WAS ADDED TO 1 MM and incuba-
tion was continued for an additional 3 hr. Bacteria were har-
vested, frozen in dry ice for 30 min, stored at −80°C, partially
thawed on ice (~ 15 min), and quickly resuspended in one-fifth
volume of MTPBS (150 mM NaCl, 16 mM Na2HPO4 and 4 mM
NaH2PO4; pH was adjusted to 7 with NaOH). All subsequent
steps were carried out at 4°C. One-tenth volume of a freshly
made 10 mg/ml lysozyme (Sigma) solution was added. After a
30-min incubation, cells were harvested by centrifugation (5000
rpm in an SS-34 Sorvall rotor for 5 min at 4°C). The cell pellet
was resuspended in the same volume of MTPBS supplemented
with 10 mM dithiothreitol (DTT; Sigma) and 1% Tween 20 (Bio-
Rad). One-milliliter aliquots were subjected to sonication at
4°C until the viscosity was reduced to that of buffer, and lysates
were incubated on ice for 1 hr. The bacterial debris and in-
soluble materials were removed by centrifugation (12,000 rpm
in a microcentrifuge for 5 min at 4°C), and supernatants were
frozen in dry ice and stored at −80°C. Supernatants were thawed
on ice and incubated for 30 min with one-twentieth volume of
a 50% glutathione–Sepharose bead suspension (Pharmacia)
equilibrated in MTPBS. The beads were pelleted and the same
volume of the 50% bead suspension was added to the superna-
tant and incubated as above. Both sets of beads were mixed and
washed three times with 10-bed volumes of MTPBS. GST or
fusion proteins were eluted off the beads by two washes with
two bead volumes of 20 mM reduced glutathione (Sigma) in 120
mM KCl and 100 mM Tris-HCl at pH 7. Aliquots of purified
proteins were stored at −80°C.
His-tagged recombinant proteins were expressed in TG1 (SF2/
ASF, SF2/ASF DRS, and SF2/ASF RS) or BL21 (RSF1 GRS) bac-
teria and purified from inclusion bodies as described (Labourier
et al. 1998).
Total SR proteins and SRp30 protein were purified from HeLa
cells or calf thymus as described (Zahler et al. 1992). Purified U1
snRNP from HeLa cells was provided by R. Lu¨hrmann (Philips
University, Marburg, Germany).
In vitro transcription, splicing assays, gel filtration, and U1
snRNP–pre-mRNA binding experiments
Radiolabeled RNAs were synthesized by in vitro transcription
in presence of 20 units of SP6 RNA polymerase (Boehringer), 1
µg of the suitable linearized plasmids, and 5 µM [a-32P]UTP (400
Ci/mmole) in 25-µl reactions according to the manufacturers.
All in vitro transcripts were purified by denaturing polyacryl-
amide–urea gels and quantitated by Cerenkov counting.
The single-intron human b-globin construct pSPHb-3A was
derived from pSP64HbD6 (Krainer et al. 1984) by inserting the
HB2T1/HB2T2 AccI–BamHI adapter between the AccI (in the
second exon) and BamHI (from pSP64) sites. The splicing reac-
tions were done under standard conditions for 1.5 hr in a total
volume of 20 µl containing 50-fmole labeled pre-mRNA and 6 µl
of HeLa nuclear extract (Dignam et al. 1983) complemented
with buffer D. Purified proteins diluted in buffer D were incu-
bated in HeLa nuclear extract for 5 min at room temperature
before addition of radiolabeled pre-mRNA. Splicing products
were analyzed by electrophoresis on denaturing 7% (Fig. 2A) or
6% (Fig. 2B) polyacrylamide gels and revealed by autoradiogra-
phy.
Gel-filtration chromatography was done essentially as de-
scribed previously (Michaud and Reed 1991; Staknis and Reed
1994). Complex assembly reactions were incubated for 30 min
at 30°C in a total volume of 250 µl containing 75 µl of HeLa
nuclear extract (Dignam et al. 1983), 1-pmole labeled pre-
mRNA, and either purified SRp30 (3.5 µl, 210 pmole) or GST–
RSF1 (20 µl, 260 pmoles). Reactions were then applied to a
2.5 × 60-cm column filled with Sephacryl S-500 equilibrated in
buffer D (Dignam et al. 1983), and 2-ml fractions were collected
at a flow rate of 2 ml/hr for Cerenkov counting.
SF2/ASF and U1 snRNP complex formation assays were per-
formed as described previously (Kohtz et al. 1994) in 20 mM
HEPES at pH 7.6, 5% glycerol, 100 mM KCl, 0.2 mM EDTA, and
1.5 mM MgCl2. Before loading half of the mixtures onto native
gels, heparin and glycerol were added to a final concentration of
1 mg/ml and 15%, respectively.
Protein–protein interaction studies
For GST-binding assays, purified GST–RSF1 or GST–RSF1DC
(150 pmoles each) were bound to 20 µl of glutathione–Sepharose
beads in buffer D for 15 min at room temperature. After two
Labourier et al.
750 GENES & DEVELOPMENT
 on December 16, 2006 www.genesdev.orgDownloaded from 
washes with buffer D, beads were then incubated with an excess
of SF2/ASF RS or RSF1 GRS protein (300 pmoles each) for 30
min at room temperature and washed extensively with buffer D.
Proteins were eluted by boiling for 5 min in SDS-loading buffer
and analyzed on a 12% SDS–polyacrylamide gel. Proteins were
revealed by Coomassie blue staining.
For Far-Western analysis, purified recombinant proteins (~ 1
µg of each), HeLa purified SR proteins (2 µg) previously treated
with 50 units of calf intestinal alkaline phosphatase for 1 hr at
30°C (to dephosphorylate them and improve their detection by
labeled probes), or purified U1 snRNP (3 µg) were run on a 12%
SDS–polyacrylamide gel and transferred to nitrocellulose by
electroblotting for 90 min in 10 mM CAPS transfer buffer at pH
11.0, containing 10% methanol. To renature the proteins, the
filters were treated as described previously (Kohtz et al. 1994)
and probed with 10 µg of labeled SF2/ASF or GST–RSF1 in 10
ml of binding buffer (Kohtz et al. 1994). To label SF2/ASF and
GST–RSF1, 10 µg of each purified recombinant protein was in-
cubated with 800 units of purified starfish cdc2 protein kinase (a
generous gift from M. Dore´e laboratory, CNRS, Montpelier,
France) in the presence of 20 µCi of [g-32P]ATP and 1 µM of cold
ATP in buffer B (Labourier et al. 1998) for 1 hr at 30°C. Unre-
acted nucleotides and cdc2 kinase were removed by binding
labeled SF2/ASF or GST–RSF1 to nickel–agarose beads or glu-
tathione–Sepharose beads, respectively. After extensive wash-
ings of the beads with buffer B, labeled proteins were eluted
with either 1 M imidazole for SF2/ASF or 20 mM glutathione for
GST–RSF1.
Drosophila stocks
The UAS–RSF1 construct was made as follows: a 1.15-kb XbaI–
XhoI RSF1 cDNA fragment, prepared from p11HX1 (see above),
was subcloned into the XhoI and XbaI sites of the pUAST vector
(Brand et al. 1994). This pUAST–RSF1 DNA was used to trans-
form w1118 flies according to standard protocols (Spradling and
Rubin 1982), except that injections employed nondechorionated
embryos. Fifteen independent UAS–RSF1 transgenic lines were
established. The transposon integration sites were mapped to
individual chromosomes by standard crosses using balancer
stocks. Three homozygous viable lines (3, 5, and 6) were used in
this report. These transformed flies were crossed to homozy-
gous (GMR–GAL4, sca–GAL4, or da–GAL4) GAL4-expressing
lines and scored for phenotypes under a stereomicroscope. Most
GAL4 lines were from the Bloomington Stock Center. The sca–
GAL4 line (Y.N. Jan, unpubl.) was provided by M. Vervoord
(CNRS, Toulouse, France). All flies were reared at 18–28°C on
standard medium. Homozygous double insert lines were ob-
tained by standard crosses using balancer stocks.
Determination of UAS–RSF1, UAS-B52 transgene expression
and developmental Northern blot analysis
Total RNAs or proteins were purified from 20 larvae of the
following genotypes: (GMR–GAL4/+; UAS–lacZ/+), (GMR–
GAL4/+; UAS–RSF13/+), (GMR–GAL4/UAS–B52) and (GMR–
GAL4/UAS–B52; UAS–RSF13/+) with 1 ml of Trizol reagent
(GIBCO-BRL). RNAs were treated subsequently with 2 units of
RQ1 DNase (Promega) for 15 min at 34°C and quantitated by
UV absorbance determination. Reverse transcriptions were car-
ried out with 400 units of M-MLV reverse transcriptase
(GIBCO-BRL), 5 µg of total RNA, and 350 µg of poly(dT)15
primer in a final volume of 50 µl. PCRs were performed with
1.25, 2.5, or 5 µl of the RT reactions, 20 pmole of each primer
(UAS1 and 21F2 for UAS–RSF1, UAS1 and B52A for UAS–B52,
copiaS and copiaA for the Drosophila retrotransposon copia),
100 µM dNTP, 1 mM MgCl2, 2.5 units of Taq DNA polymerase
(GIBCO-BRL), and 2 µCi [µ-32P] dCTP in a final volume of 50 µl.
After 20 cycles of PCR (30 sec at 60°C, 1 min at 72°C, 30 sec at
95°C), 2 µl of each PCR reaction was boiled for 3 min, loaded
onto a 5% denaturing polyacrylamide gel, and amplified frag-
ments were revealed by autoradiography.
Total proteins from transgenic larvae or HeLa nuclear extract
(~ 30 µg) were run on 12% SDS–polyacrylamide gels and trans-
ferred to nitrocellulose by electroblotting for 90 min in 10 mM
CAPS transfer buffer (pH 11.0), containing 10% methanol. Blots
were probed with mAb104 (Roth et al. 1991). A horseradish
peroxidase-conjugated anti-mouse IgM (Sigma) and the ECL re-
agent (Amersham) were used for visualization of mAb104-reac-
tive proteins.
Northern blot analysis was done as described (Brand and Bour-
bon 1993) using the largest RSF1 cDNA insert (Brand et al. 1995)
as a probe.
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